Rationale of the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines

Post time 2024-4-5 02:03:11

journal：Hypertension

Authors：Giuseppe Mancia; Mattias Brunstrom; Michel Burnier; Guido Grassi; Andrzej Januszewicz; Sverre E. Kjeldsen; Maria L. Muiesan; Costas Thomopoulos; Konstantinos Tsioufis; Reinhold Kreutz

Published date：--

DOI：10.1161/hypertensionaha.124.22821

PDF link：https://www.ahajournals.org/doi/ ... ENSIONAHA.124.22821

Article link：http://dx.doi.org/10.1161/hypertensionaha.124.22821

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

Post time 2024-4-5 02:03:12

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AHA] Rationale of the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[AHA] Rationale of the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[AHA] Rationale of the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines